1. Development and validation of the CAIL prognostic score in non‐small cell lung cancer patients with malignant pleural effusion
   Tianyuan Li et al, 2023, The Clinical Respiratory Journal CrossRef
2. Malignant Pleural Effusions in the Era of Immunotherapy and Antiangiogenic Therapy
   Terrence Wong et al, 2023, Seminars in Respiratory and Critical Care Medicine CrossRef
3. Intra-pleural and intra-peritoneal tocilizumab therapy for managing malignant pleural effusions and ascites: The Regional Immuno-Oncology Trial (RIOT)−2 study protocol
   Hyun Park et al, 2024, Surgical Oncology Insight CrossRef
4. Aptamer-siRNA chimera and gold nanoparticle modified collagen membrane for the treatment of malignant pleural effusion
   Wen Chen et al, 2022, Frontiers in Bioengineering and Biotechnology CrossRef
5. Engineered lactococcus lactis intrapleural therapy promotes regression of malignant pleural effusion by enhancing antitumor immunity
   Yue Fan et al, 2024, Cancer Letters CrossRef
6. Development of machine learning-based malignant pericardial effusion-related model in breast cancer: Implications for clinical significance, tumor immune and drug-therapy
   Wendi Zhan et al, 2024, Heliyon CrossRef
7. Case report: Envafolimab combined with Endostar in the treatment of advanced non-small cell lung cancer with malignant pleural effusion
   Changhong Dong et al, 2024, Frontiers in Oncology CrossRef
8. A review on targeting tumor microenvironment: The main paradigm shift in the mAb-based immunotherapy of solid tumors
   Ayuob Aghanejad et al, 2022, International Journal of Biological Macromolecules CrossRef
9. Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab + Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer
   Junjie Hou et al, 2022, Journal of Oncology CrossRef